Author:
Khan Shariq Mansoor,Carter Gregory T.,Aggarwal Sunil K.,Holland Julie
Abstract
Objective: Stroke and traumatic brain injury (TBI) are among the leading causes of disability. Even after engaging in rehabilitation, nearly half of patients with severe TBI requiring hospitalization are left with major disability. Despite decades of investigation, pharmacologic treatment of brain injury is still a field in its infancy. Recent clinical trials have begun into the use of psychedelic therapeutics for treatment of brain injury. This brief review aims to summarize the current state of the science's relevance to neurorehabilitation, and may act as a resource for those seeking to understand the precedence for these ongoing clinical trials.Methods: Narrative mini-review of studies published related to psychedelic therapeutics and brain injury.Results: Recent in vitro, in vivo, and case report studies suggest psychedelic pharmacotherapies may influence the future of brain injury treatment through modulation of neuroinflammation, hippocampal neurogenesis, neuroplasticity, and brain complexity.Conclusions: Historical data on the safety of some of these substances could serve in effect as phase 0 and phase I studies. Further phase II trials will illuminate how these drugs may treat brain injury, particularly TBI and reperfusion injury from stroke.
Subject
Clinical Neurology,Neurology
Reference85 articles.
1. Psychedelics as medicines: an emerging new paradigm;Nichols;Clin Pharmacol Ther.,2017
2. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders;Vollenweider;Nat Rev Neurosci.,2020
3. Algernon Pharmaceuticals2021
4. The use of psychedelics in the treatment of disorders of consciousness
GosseriesO
MartialC
31024740ALIUS BULLETIN: Exploring the Diversity of Consciousness2021
5. Psychedelics as anti-inflammatory agents;Flanagan;Int Rev Psychiatry.,2018
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献